NaviFUS

NaviFUS Financial Leverage

The Financial Leverage (Equity Multiplier) of NaviFUS (6872.TWO) as of Nov 9, 2026 is 1.14. In the previous year, Financial Leverage (Equity Multiplier) was 1.14 — a change of 0.81% (higher).

Financial Leverage

1.14

YoY

0.81%

Last updated:

Financial Leverage (Equity Multiplier) of NaviFUS is 2025 1.14 . Financial Leverage (Equity Multiplier) of NaviFUS was 2024 1.14 . It decreases by 0.81% higher compared to the previous year.

The NaviFUS Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.08 TWD
Jan 1, 2020
1.08 TWD
Jan 1, 2021
1.08 TWD
Jan 1, 2022
1.08 TWD
Jan 1, 2023
1.16 TWD
Jan 1, 2024
1.14 TWD
Jan 1, 2025
1.14 TWD
The NaviFUS Financial Leverage history
YEARFinancial LeverageYoY
1.14+0.81%
1.14-2.09%
1.16+7.31%
1.08+0.10%
1.08+0.33%
1.08+0.09%
1.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NaviFUS Stock analysis

What does NaviFUS do? NaviFUS Corp, listed on the Taiwan Stock Exchange under ticker 6872.TWO with ISIN TW0006872005, is a health care company headquartered in Taipei City, Taiwan. The company went public on June 22, 2022. NaviFUS Corp operates as a medical device company specializing in the development of two core technology platforms: focused ultrasound systems and therapeutic guidance tracking systems. The firm's focus includes the development of medical systems targeting recurrent brain tumors and Alzheimer's disease. The company's website is https://navifus.com/. NaviFUS Corp is engaged in the health care sector, specifically within the health care industry. The company's operations are centered on advancing medical technologies for neurological conditions, with an emphasis on non-invasive treatment approaches. While the company's specific products and market presence are not detailed in the provided information, its technological focus suggests a commitment to innovative solutions in neurology and neurosurgery. The firm's public listing in 2022 marks its transition into a publicly traded entity, reflecting its growth and development in the medical device sector. NaviFUS Corp's headquarters in Taipei City positions it within Taiwan's growing health care technology landscape, contributing to regional advancements in medical innovation. NaviFUS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NaviFUS stock

Financial Leverage (Equity Multiplier) of NaviFUS is 1.14 in 2025.

Financial Leverage (Equity Multiplier) of NaviFUS changed from 1.14 to 1.14, representing a 0.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) NaviFUS since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s NaviFUS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — NaviFUS

All Key Metrics — NaviFUS